J&J Pulls Yondelis NDA For Ovarian Cancer Ahead Of Final Survival Data Release
This article was originally published in The Pink Sheet Daily
Executive SummaryFaced with the prospect of having to conduct another Phase III study, Johnson & Johnson opted to withdraw the trabectedin application and is reviewing the drug's clinical development program in recurrent ovarian cancer.
You may also be interested in...
Labeling for second-line approval in rare soft tissue sarcomas cites progression-free survival benefit, with no significant survival improvement, in Phase III trial.